Author

S. Haile

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biophysics· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:chromatin & epigenetic regulation· 1 Organism:mouse· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

A. Aalipour· 1 shared A. Majumdar· 1 shared A. R. Hacker· 1 shared A. S. Wenokur· 1 shared C. K. Ngandu· 1 shared C. L. Mackall· 1 shared C. Wolberger· 1 shared D. E. Shorb· 1 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Aalipour

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The ASCC2 CUE domain contacts adjacent ubiquitins to recognize K63-linked polyubiquitin

P. M. Lombardi, S. Haile, T. Rusanov, R. Rodell, R. Anoh, J. G. Baer, K. A. Burke, L. N. Gray, A. R. Hacker, K. R. Kebreau, C. K. Ngandu, H. A. Orland, E. Osei-Asante, D. P. Schmelyun, D. E. Shorb, , C. Wolberger

This study shows that the ASCC2 CUE domain binds K63-linked diubiquitin by interacting with both ubiquitins, with unique contacts to the proximal ubiquitin that are critical for ASCC2 recruitment during DNA alkylation response.

bioRxiv · Oct 17, 2021 · PreprintBiophysics

Allogeneic CAR-invariant Natural Killer T Cells Exert Potent Antitumor Effects Through Host CD8 T cell Cross-Priming

F. Simonetta, J. K. Lohmeyer, T. Hirai, K. Maas-Bauer, M. Alvarez, A. S. Wenokur, J. Baker, A. Aalipour, X. Ji, S. Haile, C. L. Mackall, R. S. Negrin

This study shows allogeneic CAR-iNKT cells effectively combat tumors in mice by directly attacking cancer cells and boosting host CD8 T cell responses, even across major MHC barriers.

bioRxiv · Feb 3, 2021Immunology